Recruiting

Observational Study

Sponsor:

Scott Raymond

Code:

NCT07798323

Conditions

Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

Conditions

Macular Degeneration

Study ID

NCT07798323

Start date

Sep 1, 2026

Status verified date

Sep, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 50-80 years of age
  • All genders
  • Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
  • Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio

Exclusion Criteria:

  • Poor image quality that limits quantification
  • GA extending beyond the borders of the SDOCT field of view.
  • Bilateral symmetric geographic atrophy.
  • Diagnosis of wet AMD.
  • Any retinal fluid at baseline.
  • Other concurrent retinal diseases
  • Vitreoretinal surgery.
  • Allergy to iodinated contrast agents.
  • Chronic kidney disease with eGFR < 60

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA. [ Time Frame: From enrollment to the end of the 12-month study period. ]

Central Contacts and Locations

Central contacts

Sara Lautzenhiser Research Coordinator

216-444-3026LAUTZES@ccf.org

Locations

Cleveland Clinic

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Sara Lautzenhiser Research Coordinator

216-444-3026LAUTZES@ccf.org

Principal Investigator:

Scott Raymond, MD

More Information

Sponsor

Scott Raymond

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Scott Raymond on 2026-09-03.